Sun Pharmaceutical Industries share news, announcements and annual reports
NSE: SUNPHARMABSE: 524715Pharmaceuticals & BiotechnologyLarge Cap
Sun Pharmaceutical Industries Limited · Formerly Sun Pharmaceuticals Industries · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Dec 1994 on BSE, Feb 1995 on NSE
Last close ₹1,770.00down ₹7.70 (0.43%)BSE ₹1,768.00
Share price at the NSE close on 2 Nov 2026. Previous close ₹1,777.70.
2 Nov: open ₹1,770.00, high ₹1,776.20, low ₹1,722.00
52-week range of traded prices to 2 Nov 2026
₹1,583.70Low, 29 Jan 2026₹2,046.90High, 31 Jul 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹4,24,682 Cr13th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 38.73
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹1,962 crore of one-off items, the largest of them in the quarter to Sep 2026.
- 32.85
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.76
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.90%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 13.1%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹1,962 crore of one-off items, the largest of them in the quarter to Sep 2026.
- 15.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 16.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.03
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 34,57,79149.8% delivered
Sun Pharmaceutical Industries share news and announcements
1,454 announcements, routine notices left out, newest first. Page 21 of 30.
Dec 2014
1 Dec · Business
Sun Pharmaceuticals Industries Limited had informed the Exchange vide announcement dated November 24, 2014 regarding the Approval of Scheme of Arrangement between Ranbaxy Laboratories Limited with Sun Pharmaceutical Industries Ltd in the nature of merger of Ranbaxy Laboratories Limited with the Company. The Company has now informed that Foreign Investment Promotion Board (FIPB) has, as per the press release dated November 28, 14 released by FIPB unit of Ministry of Finance, Department of Economic Affairs, approved the proposal of the Company for issuing equity shares of the Company to the non-resident investors of Ranbaxy Laboratories Limited pursuant to the merger of Ranbaxy Laboratories Limited into Sun Pharmaceutical Industries Limited through the scheme of arrangement between Ranbaxy Laboratories Limited and Sun Pharmaceutical Industries Limited.
Nov 2014
17 Nov · Legal
Exchange had sought clarification from Sun Pharmaceuticals Industries Limited with respect to a news item captioned "Sun Pharma Merck Call Off 3-year-old JV". The Company has clarified as follows: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. Company's Response : "There is no termination of JV of Sun Pharma with Merck (MSD)". b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. If so, you are advised to provide the said information and the reasons for not disclosing the same to the Exchange earlier as required under clause 36 of the Listing Agreement. Company's Response : "No".17 Nov · Legal
Exchange has sought clarification from Sun Pharmaceuticals Industries Limited with respect to recent news item captioned "Sun Pharma Merck Call Off 3-year-old JV". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. The response from the Company is awaited.13 Nov · Business
Board of Directors has passed Resolution at their meeting held on November 13, 2014 approving subject to the approval of SEBI, Stock Exchanges the High Court of Gujarat at Ahmedabad, Shareholders and Creditors of the Company and other required governmental and / or regulatory authorities, as may be applicable and required the Scheme of Amalgamation under Sections 391 to 394 of the Companies Act, 1956 for Merger of Sun Pharma Global Inc, a wholly owned foreign subsidiary of our Company, into the Company, Sun Pharmaceutical Industries Ltd without any consideration w.e.f. January 01, 2015 as per the draft Scheme of Amalgamation.
Oct 2014
29 Oct · Board meeting
Inter alia, to consider and take on record the un-audited financial results of the Company for the second quarter ended September 30, 2014.17 Oct · Legal
Exchange had sought clarification from Sun Pharmaceuticals Industries Limited with respect to news item captioned "Sun, Ranbaxy may be asked to sell some business for CCI approval to merger". The Company has clarified that "(a) We have not received any direction from the Competition Commission of India (CCI) for divesting any business as indicated in the said news article. (b) Further, the Company is not aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement".9 Oct · Legal
Exchange had sought clarification from Sun Pharmaceuticals Industries Limited with respect to a news item captioned "Sun, Dr Reddy's, cadila named in US Congress price probe". The Company has clarified that "We confirm that our subsidiary company has received recently a data request from Representative Cummins and Senator Sanders relating to the price increase of 3 products being distributed by Sun Pharma subsidiary in the US market. The article has no material impact on the Company".1 Oct · Disclosure of Voting Pattern - Clause 35A
Sep 2014
15 Sep · Legal
Exchange had sought clarification from Sun Pharmaceuticals Industries Limited with respect to news item captioned "Sun Pharma to raise Rs. 12K cr via QIP". The Company has clarified that "Resolutions proposed for approval of the shareholders of the Company at the ensuing 22nd Annual General Meeting to be held on September 27, 2014 regarding issue of securities upto Rs.120 Billions and for borrowings upto Rs.500 bn. are only enabling resolutions. Last year also resolution was proposed for approval of and was approved by the shareholders of the Company at the 21st Annual General Meeting held last year regarding issue of securities almost in the same manner upto the same amount upto Rs.120 Billions as an enabling resolution. Even the resolution seeking shareholder approval, under the new Companies Act 2013, for upper limit of borrowings up to Rs.500 bn was also earlier proposed for approval to and was approved by the shareholders of the Company at the 21st Annual General Meeting held last year with the same upper cap of Rs. 500 billions. There is no material impact of the matter referred to in the article on the performance / operations of the Company."12 Sep · Legal
Exchange had sought clarification from Sun Pharmaceuticals Industries Limited with respect to a news item captioned "US FDA descends on Sun Pharma's Halol unit". The Company had clarified that "Sun Pharma and its subsidiary have more than 15 manufacturing facilities spread across India. It markets products in more than 50 countries; each country has its own pharma regulatory requirements. These manufacturing facilities undergo many routine regulatory inspections from several of these countries as part of normal course of business, from time to time. Conduct of each of these inspections per se has no material impact. Also, informing the stock exchange for every such inspection, which in itself is not material, may be construed inappropriately. If there are any material developments, related to or coming out of such inspections, we will keep the stock exchanges and investors informed of such material developments. Please note there is no material impact of the matter referred to in the article on the performance / operations of the Company".
Aug 2014
26 Aug · Disclosure of Voting Pattern - Clause 35A
13 Aug · Corporate action
Register of Members and Share Transfer Books of the Company will be closed from September 13, 2014 to September 27, 2014 (both days inclusive) for the purpose of payment of dividend and for holding of Annual General Meeting.13 Aug · Board meeting
Board of Directors of the Company at its meeting held on August 12, 2014 has recorded approval of Scheme of Arrangement & Reconstruction between Sun Pharmaceutical Industries Ltd., and Sun Pharma Global FZE in the nature of demerger and transfer of the Specified Undertaking of Sun Pharma Global FZE to the Company with effect from the appointed date of May 01, 2013 as per the order of the Hon'ble High Court of Gujarat, at Ahmedabad at Its hearing held on July 10, 2014 and accordingly after taking into effect of the above Scheme, approved the revised annual accounts for the year ended March 31, 2014.13 Aug · Dividend
Payment of dividend would be made on or before September 30, 2014.13 Aug · Management
At the Board Meeting of the Company held on August 12, 2014, Mr.Uday Baldota has been appointed as the Chief Financial Officer (CFO) of the Company, as per section 203 of the Companies Act, 2013, with immediate effect.13 Aug · Dividend
Board of Directors of the Company at its meeting held on August 12, 2014 has recommended payment of dividend of Rs. 1.50 (Rupees One and Fifty paise) per equity share of Re.1/- each of the Company for the year ended March 31, 2014, subject to the approval of the members at the ensuing Annual General Meeting of the Company.
Jul 2014
30 Jul · Board meeting
Board of Directors of the Company would meet on August 12, 2014 to transact, inter alia, the following business. (i) Consider the revised audited annual accounts of the Company for the year ended March 31, 2014 after giving the effect to the above mentioned Scheme of Arrangement and Reconstruction between SPIL and SPGFZE. (ii) To consider the recommendation of payment of dividend on equity shares for the year ended March 31, 2014 subject to the approval of the shareholders at the ensuing Annual General Meeting. (iii) To consider and take on record the un-audited financial results of the Company for the first quarter ended June 30, 2014 (Q1). The window closure for Trading by Designated persons as per Insider Trading Rules of the Company will be from August 01, 2014 to August 14, 2014 (both days inclusive).30 Jul · Business
Hon'ble High Court of Gujarat, at Ahmedabad at its hearing held on July 10, 2014 has approved the Scheme of Arrangement and Reconstruction between Sun Pharmaceutical Industries Limited (SPIL) and Sun Pharma Global FZE (SPGFZE) in the nature of demerger and transfer of the specified Undertaking of SPGFZE to SPIL with effect from the appointed date of May 01, 2013. Further to inform that the certified copy of the High Court order is expected to be received shortly and will be filed with the Registrar of Companies there after as required and the demerger process would get completed on such filing
May 2014
29 May · Board meeting